Technical Analysis for JUNO - Juno Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
JUNO closed up 51.86 percent on Wednesday, January 17, 2018, on 8.72 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The bulls were able to push the stock to a new 52-week high.
|Weak or Absent||Up||Up||Up|
|See historical JUNO trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 17||Crossed Above 50 DMA||Bullish||0.00%|
|Jan 17||MACD Bullish Centerline Cross||Bullish||0.00%|
|Jan 17||New 52 Week Closing High||Bullish||0.00%|
|Jan 17||Volume Surge||Other||0.00%|
|Jan 17||New 52 Week High||Strength||0.00%|
|Jan 17||Wide Bands||Range Expansion||0.00%|
|Jan 17||Above Upper BB||Strength||0.00%|
|Jan 17||Gapped Up||Strength||0.00%|
|Jan 17||Overbought Stochastic||Strength||0.00%|
|Jan 16||Wide Bands||Range Expansion||51.86%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. The company's additional product candidates comprise CD171, a cell-surface adhesion molecule to treat neuroblastoma; MUC-16, a protein for treating ovarian cancers; IL-12, a cytokine to overcome the inhibitory effects; ROR-1, a protein for the treatment of non-small cell lung, triple negative breast, pancreatic, and prostate cancers; and WT-1, an intracellular protein to treat adult myeloid leukemia and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers. It has license and collaboration agreements with Fred Hutchinson Cancer Research Center and Memorial Sloan Kettering Cancer Center; and license agreement with St. Jude Children's Research Hospital. The company was formerly known as FC Therapeutics, Inc. and changed its name to Juno Therapeutics, Inc. in October 2013. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more JUNO news...
|52 Week High||70.0|
|52 Week Low||19.07|
|200-Day Moving Average||36.9861|
|50-Day Moving Average||52.3504|
|20-Day Moving Average||48.091|
|10-Day Moving Average||50.499|
|Average True Range||4.1799|
|Chandelier Exit (Long, 3 ATRs )||57.4603|
|Chandelier Exit (Short, 3 ATRs )||54.8297|
|Upper Bollinger Band||58.4527|
|Lower Bollinger Band||37.7293|
|Percent B (%b)||1.52|
|MACD Signal Line||-0.5078|
|Market Cap||7.27 Billion|
|Num Shares||105 Million|
|Price-to-Earnings (P/E) Ratio||-24.47|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||76.44|
|Resistance 3 (R3)||75.89||72.94||75.24|
|Resistance 2 (R2)||72.94||71.11||73.22||74.84|
|Resistance 1 (R1)||71.10||69.98||72.02||71.65||74.44|
|Support 1 (S1)||66.31||66.32||67.23||66.86||64.06|
|Support 2 (S2)||63.36||65.19||63.64||63.66|
|Support 3 (S3)||61.52||63.36||63.26|
|Support 4 (S4)||62.07|